أمل جديد لمرضى السرطان: عقار أميفانتاماب يحقق نتائج

Johnson & Johnson announced pivotal results from the Phase 1b/2 OrigAMI-4 study on May 31, 2026, reporting that subcutaneous amivantamab (Rybrevant Faspro) delivered strong and durable responses in patients with advanced head and neck squamous cell carcinoma (HNSCC) who had progressed after standard immunotherapy and chemotherapy . The data address a critical unmet need in a disease where effective later-line therapies are scarce.

Efficacy: Strong Responses with Deep Remissions

The trial's primary analysis, based on blinded independent central review (BICR), demonstrated a confirmed overall response rate (ORR) of 42% (95% confidence interval [CI], 32-52) . More telling than the ORR alone is the depth of those responses: more than one-third of responders achieved a complete response (CR), meaning their tumors could no longer be detected on imaging scans .

Crucially, the benefits appear to be lasting. The median duration of response (DOR) had not been reached at the time of the data cut-off, with a median follow-up of 11.8 months . This suggests that for patients who do respond, the remissions can be durable, which is a significant outcome in the relapsed/refractory metastatic setting.

The study results were presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting , underscoring their importance to the oncology community.

Safety and Population Context

Detailed safety data and a full breakdown of baseline patient characteristics from the pivotal analysis were not disclosed in the initial press release. The reported population consisted of patients with advanced HNSCC previously treated with immunotherapy and chemotherapy , representing a heavily pre-treated group for whom standard options have been exhausted.

While comprehensive side-effect profiles are pending publication, data from an earlier Cohort 1 of the same OrigAMI-4 study provides some context. That cohort, evaluating subcutaneous amivantamab monotherapy in a similar post-platinum/post-immunotherapy population, showed the safety profile was consistent with the known profile of the EGFR/MET bispecific antibody class .

How Amivantamab Works: A Three-Pronged Attack

The drug's clinical activity in a notoriously difficult-to-treat cancer stems from its unique multi-modal mechanism of action. Amivantamab is a fully human, low-fucose, bispecific antibody that simultaneously targets epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) .

1. Ligand Blockade and Receptor Signaling Suppression

Amivantamab binds directly to the extracellular domain III of EGFR at specific residues (K443, K465, I467, and S468) and to the Sema domain of the MET receptor . This competitive binding physically prevents the natural ligands—including EGF, TGF-α, and HGF—from docking onto the receptors. By doing so, it blocks receptor dimerization and the resulting downstream signal transduction that drives tumor cell proliferation and survival .

2. Forcing Receptor Degradation

Beyond simply blocking signals, amivantamab actively removes the target receptors from the cancer cell surface. It triggers rapid internalization of the antibody–receptor complex into the cytoplasm, where the receptors are degraded . The drug also engages monocytes and macrophages to physically extract the bound receptors from the tumor cell through a process called trogocytosis, further starving the cancer cell of survival signaling even in the absence of ligands .

3. Recruiting the Immune System

The antibody was engineered with a low-fucose Fc region, a deliberate design choice that enhances its ability to recruit and activate immune effector cells . This allows amivantamab to potently induce antibody-dependent cellular cytotoxicity (ADCC), where natural killer cells recognize the antibody-coated tumor cell and destroy it . Interestingly, MET expression on tumor cells has been shown to enhance amivantamab's binding to EGFR and further boost this immune-mediated killing activity .

Summary

The OrigAMI-4 pivotal data represent a notable advance for a patient group with few remaining options. A 42% ORR—with a large proportion being deep, complete responses—and an immature median duration of response signal that amivantamab's three-pronged mechanism of EGFR/MET blockade and immune activation translates into clinically meaningful, durable tumor control.

Key survival metrics, including median overall survival (OS) and median progression-free survival (PFS), have not yet been reported and will be critical to fully evaluating the drug's impact. Full trial data and a detailed safety analysis are expected in a forthcoming peer-reviewed publication or medical conference presentation.